Company news

Personalis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study

April 4, 2023

Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023

March 21, 2023

Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

March 6, 2023

Personalis Appoints Christopher Hall as Chief Executive Officer

March 1, 2023

Personalis Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results

February 8, 2023

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

February 2, 2023

Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

January 3, 2023

Personalis Announces CEO Retirement and Transition

December 13, 2022

Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer

November 29, 2022

Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference

November 20, 2022

Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

November 6, 2022

Personalis Reports Third Quarter 2022 Financial Results

November 1, 2022

Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business

October 30, 2022

Personalis to Announce Third Quarter 2022 Financial Results

October 18, 2022

Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer

October 3, 2022

Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

August 29, 2022

Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics

August 16, 2022

Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers

August 14, 2022

Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

August 3, 2022

Personalis Reports Second Quarter 2022 Financial Results

August 2, 2022

Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics

August 1, 2022

Personalis to Announce Second Quarter 2022 Financial Results

July 19, 2022

Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease

July 11, 2022

Personalis Reports First Quarter 2022 Financial Results

May 3, 2022

Personalis to Present at Upcoming Investor Conferences

April 27, 2022

Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma

April 25, 2022

Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales

April 20, 2022

Personalis to Announce First Quarter 2022 Financial Results

April 19, 2022

Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene

April 11, 2022

Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform

April 11, 2022

Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022

April 10, 2022

Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference

March 30, 2022

Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors

March 23, 2022

Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022

March 22, 2022

Personalis Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

Personalis to Present at the Cowen 42nd Annual Health Care Conference

February 22, 2022

Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection

February 14, 2022

Personalis to Announce Fourth Quarter and Full-Year Financial Results

February 9, 2022

Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 31, 2022

Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

January 5, 2022

Personalis to Participate in the 24th Annual Needham Virtual Growth Conference

December 27, 2021

Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity

December 15, 2021

Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference

November 17, 2021

Personalis Named to Inc.'s 2021 Best-Led Companies List

November 11, 2021

Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

November 10, 2021

Personalis Reports Third Quarter 2021 Financial Results

November 3, 2021

Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers

November 1, 2021

Personalis Publishes New Data Demonstrating Performance and Utility of SHERPA for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

October 25, 2021

Personalis Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform

October 25, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks